Movement Alert｜RemeGen Rises 5.49% in Regular Trading, Core Product Telitacicept Included in New National Essential Drug List

Market Focus07-10

On July 10, RemeGen rose 5.49% in regular trading, trading at HK$86.15/share, with turnover of HK$162 million. The rally was driven by the official release of the National Essential Drug List on July 9, marking the first revision in eight years and the first time innovative drugs were included in the selection scope.

RemeGen's core product Telitacicept was selected as one of only four domestic Class I new drugs on the list. The drug has been approved for five major indications — systemic lupus erythematosus, rheumatoid arthritis, generalized myasthenia gravis, Sjogren's syndrome, and IgA nephropathy — with a potential domestic patient population exceeding 10 million. The broader HK-listed innovative drug sector rallied in sympathy, with Innocare Pharma also gaining over 5%, while WuXi AppTec, WuXi Biologics, and Ascentage Pharma rose more than 4%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1119814143?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-10 10:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1119814143","market":"us","top_or_hot":-1,"title":"Movement Alert｜RemeGen Rises 5.49% in Regular Trading, Core Product Telitacicept Included in New National Essential Drug List","media":"Market Focus","content":"<p><p>On July 10, RemeGen rose 5.49% in regular trading, trading at HK$86.15/share, with turnover of HK$162 million. The rally was driven by the official release of the National Essential Drug List on July 9, marking the first revision in eight years and the first time innovative drugs were included in the selection scope.</p><p>RemeGen's core product Telitacicept was selected as one of only four domestic Class I new drugs on the list. The drug has been approved for five major indications — systemic lupus erythematosus, rheumatoid arthritis, generalized myasthenia gravis, Sjogren's syndrome, and IgA nephropathy — with a potential domestic patient population exceeding 10 million. The broader HK-listed innovative drug sector rallied in sympathy, with Innocare Pharma also gaining over 5%, while WuXi AppTec, WuXi Biologics, and Ascentage Pharma rose more than 4%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜RemeGen Rises 5.49% in Regular Trading, Core Product Telitacicept Included in New National Essential Drug List</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜RemeGen Rises 5.49% in Regular Trading, Core Product Telitacicept Included in New National Essential Drug List\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-10 10:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 10, RemeGen rose 5.49% in regular trading, trading at HK$86.15/share, with turnover of HK$162 million. The rally was driven by the official release of the National Essential Drug List on July 9, marking the first revision in eight years and the first time innovative drugs were included in the selection scope.</p><p>RemeGen's core product Telitacicept was selected as one of only four domestic Class I new drugs on the list. The drug has been approved for five major indications — systemic lupus erythematosus, rheumatoid arthritis, generalized myasthenia gravis, Sjogren's syndrome, and IgA nephropathy — with a potential domestic patient population exceeding 10 million. The broader HK-listed innovative drug sector rallied in sympathy, with Innocare Pharma also gaining over 5%, while WuXi AppTec, WuXi Biologics, and Ascentage Pharma rose more than 4%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09995","symbol_name":"荣昌生物","start_time":0,"source_url":"","article_id":"1119814143","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1119814143","pubTimestamp":1783649237,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 10, RemeGen rose 5.49% in regular trading, trading at HK$86.15/share, with turnover of HK$162 million. The rally was driven by the official release of the National Essential Drug List on July...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09995":"荣昌生物"},"translate_title":"走势预警|RemeGen常规交易大涨5.49%，核心产品Telitacicept纳入新的国家基本药物目录","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09995":1},"content_text":"On July 10, RemeGen rose 5.49% in regular trading, trading at HK$86.15/share, with turnover of HK$162 million. The rally was driven by the official release of the National Essential Drug List on July 9, marking the first revision in eight years and the first time innovative drugs were included in the selection scope.RemeGen's core product Telitacicept was selected as one of only four domestic Class I new drugs on the list. The drug has been approved for five major indications — systemic lupus erythematosus, rheumatoid arthritis, generalized myasthenia gravis, Sjogren's syndrome, and IgA nephropathy — with a potential domestic patient population exceeding 10 million. The broader HK-listed innovative drug sector rallied in sympathy, with Innocare Pharma also gaining over 5%, while WuXi AppTec, WuXi Biologics, and Ascentage Pharma rose more than 4%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1119814143","isCrawlerRequest":true}